Interestingly, the mRNA level of the mid-stage differentiation marker osteocalcin was decreased in mouse FD amples but increased in human FD samples, and in both cases, the late-stage differentiation marker sclerostin was dramatically upregulated after RANKL inhibition. Here, SOST is linked to Fabry disease.